Coronavirus Disease 2019 (COVID-19)
FDA is working with U.S. government partners, including CDC, and international partners to address the pandemic.
Topic Paragraphs
Featured Topics
FDA Monkeypox Response
The FDA’s multipronged response to monkeypox includes efforts in the areas of diagnostics, vaccines and therapeutics.
Infant Formula Information and Resources
The FDA continues to work around the clock with our government partners and industry to ensure there's adequate infant formula available wherever and whenever parents and caregivers need it.
Recent Press Announcements
Recalls, Market Withdrawals, & Safety Alerts
The FDA provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products. Not all recalls have press releases or are posted on this website
Dec 03
Exportadora Copramar Recalls James Farms Frozen Raspberries Due to Possible Health Risk
Food & Beverages
Nov 30
Nestlé Purina PetCare Company Voluntarily Recalls a Limited Amount of Purina Pro Plan Veterinary Diets EN Gastroenteric Low Fat Wet Dog Food Due to Labeling Error
Animal & Veterinary
Nov 29
Rocky Mountain Pies, LLC Issues Allergy Alert on Undeclared (Tree Nuts Almonds) in Red Button Vintage Creamery 31.88 oz French Silk Pie
Food & Beverages
Paragraph Header
FDA VOICES: PERSPECTIVES FROM FDA EXPERTS
FDA’s Cybersecurity Modernization Action Plan
CMAP will leverage Artificial Intelligence and Machine Learning technologies to enhance cyber detection and response capabilities.
Focusing on Prevention to Safeguard Infant Formula
FDA is working with infant formula manufacturers to maximize production and taking steps to assure the public that infant formula is and will remain safe.
FDA Continues to Advance Medicines for Children
Increasing the availability of safe and effective medicines for children is a key priority for the U.S. Food and Drug Administration.
Recently Published Guidances
Dec 05
E19 A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-Approval or Post-Approval Clinical Trials
Dec 02
Statistical Approaches to Establishing Bioequivalence
Drugs
Dec 02
ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions
Drugs